

BioSpring Ltd




Lifesciences Report
2012 (in press)

“Funds & Fundability”
Workshop June 2012


Dr Nick Pope, MBA
CEO

Start-up Co.s – 5 year windows

No. of Life Science Start-Ups





% University spin-outs




[“Mobius Life Sciences Report”](#) 2012

Start-up Co. Finance




Investment size

Number of Investments



Sectors





Why ?

- More “under the radar finance”
- New Funding model
 - Capital efficiency & value creation
 - Delayed spin-out & project funding ?
 - Bigger investment to get to trade sale
 - Fewer
 - Pharma focused & “Stealth”
- Need Patient Capital - “funding disconnect”
- Public market likely needed to grow “Beef”
- NB. Rise of OI & Crowdfunding

“Funding for Early stage Drug Discovery,
Sept 2012, NetworkedPharma.com